Granules India News

Granules India FY26 Revenue Up 20%; Q4 Earnings Call Highlights

Granules India posted FY26 revenue of ₹53,656M (+20% YoY) and net profit of ₹5,950M (+19%). Q4 revenue rose 23% YoY. Management highlighted peptide CDMO progress, capex plans, and Gagillapur FDA readiness.

Granules India FY26 Results, Dividend, Q4 Call

Granules India's FY26 revenue rose 20% to ₹53,656 million with net profit of ₹5,950 million. The Board recommended a ₹1.75 dividend. Q4 revenue grew 23% YoY to ₹14,706 million.

Granules India Plans Controlled Substance Product Expansion

Granules India aims to launch 1-2 new controlled substance products annually over next 2-3 years, with 9 applications pending approval from Gagillapur site. Company targets positive peptide CDMO performance by FY27.

Granules India Board Approves FY26 Results, Recommends ₹1.75 Dividend

Board approved audited FY26 financial results and recommended final dividend of ₹1.75 per share. 35th AGM scheduled for August 6, 2026 with dividend record date July 30.

Granules India Board Approves FY26 Results, Recommends ₹1.75 Dividend

Board approved audited FY26 financial results and recommended final dividend of ₹1.75 per share. 35th AGM scheduled for August 6, 2026 with dividend record date July 30.